Riskpilot← Back to searchSign inGet full accessLungFlex AB
ABActiveOrg 5568551419GarvarenResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20110 employees
Revenue 2025
SEK 278K
-52% vs 2024
EBITDA margin
-602.6%
-21% vs 2024
Equity ratio
-19.3%
Financial strength
Net profit 2025
SEK -1,9M
-29% vs 2024
| Revenue | SEK 278K | -52% |
| EBITDA | SEK -1,7M | -21% |
| Net profit | SEK -1,9M | -29% |
| Total assets | SEK 1,8M | +5% |
| Equity | SEK -348K | -195% |
| Employees | 0 | — |
Legal name
LungFlex AB
Org number
5568551419
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
8 juni 2011
Share capital
SEK 630 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolaget ska bedriva utveckling av medicintekniska produkter, handel och förvaltning av värdepapper och därmed förenlig verksamhet.
Address
Garvaren
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 56 | 3 | 53 | 158 | 168 | 585 | 278 |
| Staff expenses | — | — | — | — | — | — | −9 | −11 | −113 | −0 |
| EBITDA | 8 | 18 | 23 | 46 | −116 | −365 | −828 | −745 | −1 383 | −1 675 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −674 | −0 | −55 | −55 | −55 | −55 |
| EBIT | 8 | 18 | 23 | 46 | −790 | −365 | −882 | −800 | −1 437 | −1 730 |
| Net financials | −8 | −18 | −23 | −46 | −45 | −42 | −35 | −32 | −49 | −186 |
| Profit before tax | 0 | 0 | 0 | 0 | −835 | −407 | −917 | −832 | −1 486 | −1 916 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — | — |
| Net profit | 0 | 0 | 0 | 0 | −835 | −407 | −917 | −832 | −1 486 | −1 916 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 806 | 1 058 | 1 125 | 1 262 | 1 389 | 1 951 | 2 707 | 1 624 | 1 711 | 1 804 |
| Equity | 383 | 384 | 384 | 384 | 794 | 1 390 | 2 035 | 1 204 | 367 | −348 |
| Long-term debt | 324 | 589 | 725 | 687 | 405 | 349 | 218 | 86 | 1 007 | 2 000 |
| Short-term debt | 99 | 85 | 17 | 191 | 190 | 212 | 454 | 334 | 337 | 153 |
| Total debt | 423 | 674 | 742 | 878 | 595 | 561 | 671 | 420 | 1 343 | 2 153 |
EBITDA margin
-602.6%
This company
15.8%
Market median
-3914% vs market
20162025
Equity ratio
-19.3%
This company
38.2%
Market median
-151% vs market
20162025
Return on equity
-191555000.0%
This company
18.4%
Market median
-1041059883% vs market
20162025
Net profit margin
-689.1%
This company
8.1%
Market median
-8607% vs market
20162025
Asset turnover
0.15×
This company
1.12×
Market median
-87% vs market
20162025
Debt / equity
6.18×
This company
0.62×
Market median
-897% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-10-01 – 2016-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PI Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2026 | — | — | |
| Chairman | 2026 | — | — | |
| Deputy Board Member | 2026 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2024 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LungFlex AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pär Ingvar Andersson | Chief Executive Officer | 0 companies |
| Kjell Tomas Sigvard Henriksson | Chairman | 0 companies |
| Hans Rolf Tobias Andersson | Board of Directors | 0 companies |
| Per Anders Persson | Board of Directors | 0 companies |
| Emma Helena Malin Gundersen | Board of Directors | 0 companies |
| Annika Margareta Mc Crea | Chairman | 0 companies |
| Anna Charlotta Lawlor | Deputy Board Member | 0 companies |
| Sten Lars Anders Nachtweij | Board of Directors | 0 companies |
| Bengt Jonas Hansson | Board of Directors | 0 companies |
| Nils Johan Erik Blomén | Chairman | 0 companies |
| Nils Arne Nilsson | Board of Directors | 0 companies |
| Emma Kristina Jones | Board of Directors | 0 companies |